Cardiovascular risk factors and immunosuppressive regimen after liver transplantation

Transplant Proc. 2010 Sep;42(7):2576-8. doi: 10.1016/j.transproceed.2010.05.160.

Abstract

Cardiovascular and metabolic diseases represent important long-term complications after liver transplantation (LT), impairing long-term and disease-free survivals. A few mechanisms underlie the development of those complications, but the role of immunosuppressive drugs is major. Although several patients develop temporary metabolic diseases, which normalize after a short postoperative period and do not need long-term drug therapy, the incidences of de novo long-lasting arterial hypertension, hyperlipidemia, and diabetes mellitus are high during the first year after LT. The aim of this retrospective study was to evaluate new-onset arterial hypertension, hyperlipidemia, or diabetes among 100 LT patients at a single institution. We used chi-square statistical analysis to compare incidences during tacrolimus versus cyclosporine therapy. Hypertension did not seem to be more strongly related to tacrolimus than to cyclosporine, nor did diabetes, whereas there was a difference for the development of hyperlipidemia.

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Cardiovascular Diseases / epidemiology*
  • Diabetes Mellitus / chemically induced
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / epidemiology
  • Disease-Free Survival
  • Drug Therapy, Combination / adverse effects
  • Humans
  • Hyperlipidemias / chemically induced
  • Hyperlipidemias / drug therapy
  • Hyperlipidemias / epidemiology
  • Hypertension / chemically induced
  • Hypertension / drug therapy
  • Hypertension / epidemiology
  • Hypoglycemic Agents / therapeutic use
  • Hypolipidemic Agents / therapeutic use
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Liver Transplantation / adverse effects
  • Liver Transplantation / immunology*
  • Postoperative Complications / chemically induced
  • Postoperative Complications / epidemiology
  • Retrospective Studies
  • Risk Factors

Substances

  • Antihypertensive Agents
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Immunosuppressive Agents